Mechanosensing regulates pDC activation in the skin through NRF2 activation
Plasmacytoid DCs (pDCs) infiltrate the skin, chronically produce type I interferon (IFN-I), and promote skin lesions and fibrosis in autoimmune patients. However, what controls their activation in the skin is unknown. Here, we report that increased stiffness inhibits the production of IFN-I by pDCs. Mechanistically, mechanosensing activates stress pathways including NRF2, which induces the pentose phosphate pathway and reduces pyruvate levels, a product necessary for pDC responses. Modulating NRF2 activity in vivo controlled the pDC response, leading to resolution or chronic induction of IFN-I in the skin. In systemic sclerosis (SSc) patients, although NRF2 was induced in skin-infiltrating pDCs, as compared with blood pDCs, the IFN response was maintained. We observed that CXCL4, a profibrotic chemokine elevated in fibrotic skin, was able to overcome stiffness-mediated IFN-I inhibition, allowing chronic IFN-I responses by pDCs in the skin. Hence, these data identify a novel regulatory mechanism exerted by the skin microenvironment and identify points of dysregulation of this mechanism in patients with skin inflammation and fibrosis.
Authors
- Franck J. Barrat (ORCID: https://orcid.org/0000-0002-0735-0850)
- Vidyanath Chaudhary (ORCID: https://orcid.org/0000-0002-6000-7517)
- Bikash Mishra (ORCID: https://orcid.org/0000-0002-7351-2096)
- Marie Dominique Ah Kioon (ORCID: https://orcid.org/0000-0003-2319-0444)
- Mary K. Crow (ORCID: https://orcid.org/0000-0002-7881-2020)
- Lionel B. Ivashkiv (ORCID: https://orcid.org/0000-0002-9951-0646)
- Yong Du (ORCID: https://orcid.org/0000-0003-2986-6249)
Institutions
- Hospital for Special Surgery (US)
- Cornell University (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- The Journal of Experimental Medicine
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1084/jem.20240852
- Citations
- 10
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.25
Funders
- Scleroderma Research Foundation
- Eli Lilly and Company
- AstraZeneca
- Gilead Sciences
- National Institutes of Health
- Weill Cornell Medical College